Amylin Pharmaceuticals, Inc.
(NASDAQ:AMLN)|
7.62 +0.48 (6.72%) Dec 04 - Close |
|
|
|
After-Hours 7.69 +0.07 (0.92%) Thu, 4 Dec 2008 7:40 PM
- Compare AMLN with:
- View: Line | Candlestick
Company Profile
Amylin Pharmaceuticals, Inc.
9360 Towne Centre Drive
San Diego, CA 92121
United States - Map
Phone: (858) 552-2200
Fax: (858) 552-2212
Website: www.amylin.com
State of incorporation: Delaware
CEO: Daniel M. Bradbury
Employees: 1,900
Sector: Healthcare
Industry Group: Drugs
Industry: Biotechnology
Dev therapeutics based on amylin
A biopharmaceutical company engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases.
Recent news for AMLN
-
Amylin spent $540K lobbying government in 3Q
AP - 4 hours ago
-
Forbes.com - Dec 02 at 2:39 ET
-
Nine Pharma Predictions for 2009
Seeking Alpha - Dec 02 at 3:10 ET
-
Predictions: 9 For '09 In Pharma
CNBC - Dec 01 at 2:00 ET
-
A Bloody Good Deal for Johnson & Johnson
Motley Fool - Nov 24 at 3:38 ET
-
A Bloody Good Deal for Johnson & Johnson
Motley Fool - Nov 24 at 2:38 ET
-
Diabetes-Drug Makers Face FDA Hurdle
TheStreet.com - Nov 24 at 12:37 ET
-
Zacks.com - Nov 21 at 3:25 ET
-
Icahn Takes on CEOs, Makes Big Moves in Biotech
Indie Research - Nov 21 at 9:24 ET
-
[$$] Biotech Mailbag: Recap on GenVec
RealMoney by TheStreet.com - Nov 21 at 7:45 ET
Top members owning AMLN
-
Top 90%
-55.90%3m:
-56.44%YTD:
-
Top 23%
-14.09%3m:
-14.09%YTD:
-
Top 52%
-34.83%3m:
-37.35%YTD: